THE PLEIOTROPIC EFFECTS OF ATORVASTATIN WHEN COMBINED WITH

阿托伐他汀与阿托伐他汀联合使用时的多效作用

• 批准号: 7952047
• 负责人: Kathleen Colleran
• 金额: $ 1.65万
• 依托单位: UNIVERSITY OF NEW MEXICO
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7952047
• 关键词: Affect; Amlodipine; Blood Glucose; Blood Pressure; Blood Vessels; Cholesterol; Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Heart Diseases; Hydrochlorothiazide; Inflammation; Institution; New Mexico; Pharmaceutical Preparations; Research; Research Personnel; Resources; Risk Factors; Source; United States Food and Drug Administration; United States National Institutes of Health; Universities; atorvastatin; heart disease risk; improved; vascular factor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to compare how commonly used blood pressure medications, Hydrochlorothiazide [HCTZ] and Amlodipine interact with a medication used to lower cholesterol, Atorvastatin. All of these drugs are approved for these purposes by the U.S. Food and Drug Administration [FDA]. Atorvastatin has been shown to decrease cholesterol but also improve other risk factors for heart disease. However few studies have looked at how the combination of Atorvastatin and Amlodipine or HCTZ affect other vascular factors. This study will compare the effects of the cholesterol medication taken with each blood pressure medication alone on heart disease risk factors including blood pressure, cholesterol, inflammation, blood sugar control, blood vessel function and other heart disease risk factors.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 这项研究的目的是比较常用的血压药物，氢氯噻嗪[HCTZ]和氨氯地平如何与用于降低胆固醇（降低胆固醇）的药物相互作用。 所有这些药物均由美国食品药品监督管理局[FDA]批准为这些目的。 阿托伐他汀已显示可降低胆固醇，但也改善了心脏病的其他风险因素。 然而，很少有研究研究阿托伐他汀和氨氯地平或HCTZ的组合如何影响其他血管因素。这项研究将比较每种血压药物对心脏病风险因素的影响，包括血压，胆固醇，炎症，血糖控制，血管功能和其他心脏病风险因素。